Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famitinib - Jiangsu Hengrui Medicine

Next Previous
X
Search
Drug Profile

Famitinib - Jiangsu Hengrui Medicine

Alternative Names: Famitinib maleate; SHR 1020

Latest Information Update: 20 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cervical cancer
  • Phase III Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Triple negative breast cancer
  • Phase II Biliary cancer; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Osteosarcoma
  • Clinical Phase Unknown Fibroma

Most Recent Events

  • 20 Aug 2024 Discontinued - Phase-I for Nasopharyngeal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (PO)
  • 20 Aug 2024 Phase-III clinical trials in Cervical cancer (Combination therapy, First-line therapy, Late-stage disease) (PO) prior to August 2024 (Jiangsu HengRui Medicine pipeline, August 2024)
  • 30 Mar 2024 Second Affiliated Hospital of Xi'an Jiaotong University plans phase-II trial for Non small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in March 2024 (PO), (NCT06336954)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top